Plasbumin-25 Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Plasbumin-25 market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to regulatory approvals, strong product demand, competition from alternative treatments, pricing strategies, supply chain dynamics, and reimbursement policies.

The projected growth during the forecast period can be attributed to market expansion, an aging population, increasing healthcare expenditure, technological advancements, government healthcare policies, and the rising incidence of chronic diseases. Key trends expected during this period include improved manufacturing processes, greater patient awareness, rising demand for immunoglobulin therapies, a focus on sustainability in production, the development of biosimilar products, personalized medicine approaches, and regulatory changes impacting production.

The rising prevalence of liver disorders is expected to drive the growth of the plasbumin-25 market moving forward. Liver disorders, including conditions like cirrhosis, hepatitis, fatty liver disease, and liver cancer, are on the rise due to factors such as increased alcohol consumption, obesity, diabetes, and viral infections like hepatitis. Plasbumin-25 plays a crucial role in managing liver diseases by restoring albumin levels, helping to manage fluid balance, and preventing complications in conditions like cirrhosis and hepatic failure. For instance, in July 2023, the Office for Health Improvement and Disparities reported a 22% increase in hospital admissions for liver disease in England in the year ending 2022. Therefore, the growing incidence of liver disorders is fueling the demand for plasbumin-25.

The increasing number of road fatalities is expected to propel the growth of the plasbumin-25 market. Traffic accidents are a significant cause of hypovolemic shock, especially in cases of severe trauma, burns, or blood loss. Plasbumin-25 is used in emergency situations to treat shock by restoring blood volume and fluid balance. For example, in February 2023, the Statistisches Bundesamt in Germany reported that road traffic injuries rose by 5%, and fatalities increased by 13% compared to the previous year. This increase in road accidents is expected to drive the demand for Plasbumin-25 to address shock caused by such injuries.

A key trend in the plasbumin-25 market is strategic investment in plasma-derived medicines and advanced healthcare infrastructure, particularly albumin purification plants. These facilities are essential for producing Plasbumin-25 by extracting and purifying human albumin for therapeutic uses. For example, in October 2022, Grifols, a Spain-based healthcare company, inaugurated a new albumin purification plant in Dublin, which is part of their strategy to meet the growing demand for albumin-based medicines. This expansion will not only support the global supply chain but also enhance Grifols’ position in the competitive plasma-derived medicines market, ultimately benefiting the Plasbumin-25 market.

Key player operating in the plasbumin-25 market is Grifols S.A.

North America was the largest region in the plasbumin-25 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the plasbumin-25 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Plasbumin-25 is a brand of human albumin solution primarily used to restore blood volume and maintain plasma colloid osmotic pressure in patients with conditions like hypovolemia, burns, or liver cirrhosis. It aids in managing fluid balance during surgeries and in severe health conditions such as acute liver failure or shock. The 25% concentration is particularly effective for treating hypoalbuminemia and supports critical functions in patients experiencing protein loss or fluid imbalances.

Plasbumin-25 is available in packaging sizes of 50 mL, 250 mL, and 500 mL. The 50 mL packaging size is commonly used in hospitals or clinical settings for patients with moderate needs or in emergency care, offering a small, convenient dosage for short-term treatments. Its indications include hypovolemic shock, hypoproteinemia, acute respiratory distress syndrome (ARDS), cardiopulmonary bypass, and acute liver failure. Plasbumin-25 is distributed through hospitals, clinics, retail pharmacies, and specialty pharmacies, and is used by adult and geriatric patients.

The plasbumin-25 market research report is one of a series of new reports that provides plasbumin-25 market statistics, including plasbumin-25 industry global market size, regional shares, competitors with a plasbumin-25 market share, detailed plasbumin-25 market segments, market trends and opportunities, and any further data you may need to thrive in the plasbumin-25 industry. This plasbumin-25 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The plasbumin-25 market consists of sales of products including albumin solutions, immunoglobulins, clotting factors, and plasma-derived therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.